3-Acetylthio-N-methylpropionamid | 66499-78-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Acetylthio-N-methylpropionamid
• 英文别名: 3-acetylthio-N-methylpropionylamide；S-[3-(methylamino)-3-oxopropyl] ethanethioate
• CAS: 66499-78-3
• 化学式: C₆H₁₁NO₂S
• 分子量: 161.225
• InChiKey: BIAHXZAGBKIPTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Acetylthio-N-methylpropionamid 、 水 以81%的产率得到
  参考文献：
  名称：

  NYITRAI J.; FETTER J.; HORNYAK G.; ZAUER K.; LEMPERT K.; KOCZKA I.; SAGI +, TETRAHEDRON, 1978, 34, NO 7, 1031-1035

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氯-N-甲基丙酰胺 以19%的产率得到3-Acetylthio-N-methylpropionamid
  参考文献：
  名称：

  PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME

  摘要：

  公开号：

  EP0757051B1

文献信息

• CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130197205A1

  公开（公告）日：2013-08-01

  The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X 1 , X 4 , R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (α4β1) and alpha-V-beta-3 (αVβ3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.

  该发明涉及公式I的壳聚糖聚合物衍生物： 及其药用可接受的盐和酯，其中Y、X 1 、X 4 、R1、R2和n在详细说明和权利要求中有定义。公式I的壳聚糖聚合物衍生物与α4β1和αVβ3整合素二聚体结合或结合，并可用于传递制剂以将药物、核酸或其他治疗化合物传递到表达这些整合素的组织或细胞中。
• The synthesis of (3,4,5,6-tetrahydro-4-oxo-2h-1,3-thiazin-2-yl)-alkanoic acids, their derivatives and some related compounds
  作者：J. Nyitrai、J. Fetter、Gy. Hornyák、K. Zauer、K. Lempert、I. Koczka、I. Sági、Cs. Rétháti

  DOI：10.1016/0040-4020(78)88160-5

  日期：1978.1

  5,6-Dihydro-2H-1,3-thiazin-4(3H)-ones 2–10 related to the natural antituberculytic Mycobacidine 1, have been synthesised. Some of the compounds of types 2,3 and 5 proved highly active in vitro against Mycobacterium tuberculosis typ. humanus (H37Rv), but the in vitro activities are diminished or suspended in the presence of biotine.

  已经合成了与天然抗结核菌性霉菌碱1相关的5,6-二氢-2 H -1,3-噻嗪-4（3 H）-酮2-10。在体外，某些2、3和5型化合物被证明对结核分枝杆菌具有很高的活性。人（H 37 R v），但在存在生物碱的情况下体外活性减弱或中止。
• Penem derivatives and antimicrobial agent containing the same
  申请人：Ishiguro Masaji

  公开号：US20050004092A1

  公开（公告）日：2005-01-06

  A penem derivative represented by the following formula (I): wherein R 1 represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkylthio group, a substituted or unsubstituted alkenylthio group, a substituted or unsubstituted aralkylthio group, a substituted or unsubstituted arylthio group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted heterocyclic thio group, a substituted or unsubstituted acylthio group, a mercapto group or a hydrogen atom, and R 2 represents a hydrogen atom or a carboxyl-protecting group; or a pharmacologically acceptable salt thereof. The compound (I) exhibits strong antibacterial activities, and especially, shows strong activities against MRSA. It is therefore useful not only as a general antibacterial agent but also as an antibacterial agent for MRSA against which no general antibacterial agents are recognized to be-effective.

  以下是公式（I）所代表的一种青霉烷衍生物： 其中，R1代表取代或未取代的烷基、取代或未取代的烯基、取代或未取代的芳基烷基、取代或未取代的芳基、取代或未取代的烷基硫基、取代或未取代的烯基硫基、取代或未取代的芳基烷基硫基、取代或未取代的芳基硫基、取代或未取代的杂环基、取代或未取代的杂环硫基、取代或未取代的酰基硫基、巯基或氢原子，R2代表氢原子或羧酸保护基；或其药学上可接受的盐。该化合物（I）表现出强大的抗菌活性，特别是对MRSA表现出强大的活性。因此，它不仅有用作一般抗菌剂，还有用作抗MRSA的抗菌剂，对于这种细菌，一般的抗菌剂被认为无效。
• Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones
  申请人：Reddy E. Premkumar

  公开号：US20090281066A1

  公开（公告）日：2009-11-12

  Methods of treating cancer using compounds according to Formula (I) are disclosed herein, wherein X, X 1 , X 2 , R a , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , g, M, y, a, b, d, e, V, W, Z and Q are as defined herein.

  本文披露了使用公式（I）中的化合物治疗癌症的方法，其中X，X1，X2，Ra，R1，R2，R3，R4，R5，R6，R7，g，M，y，a，b，d，e，V，W，Z和Q的定义如下。
• DRUG CONJUGATES WITH POLYGLYCEROLS
  申请人：Kratz Felix

  公开号：US20110117009A1

  公开（公告）日：2011-05-19

  The present invention relates to a drug polymer conjugate comprising a pharmaceutically active compound and a dendritic polyglycerol, as well as to a drug polymer conjugate comprising a pharmaceutically and/or diagnostically active compound bound to a dendritic polyglycerol core having a polyethylene glycol shell.